Patient Profile

Suitable Candidates

  1. Patients with generalized pustular psoriasis, erythrodermic psoriasis and localized pustular psoriasis
  2. For severe plaque-type psoriasis, treatment is most effective when combined with other therapies

Unsuitable Candidates

  1. Best avoided by women of childbearing age, because of the high risk of fetal abnormalities if pregnancy occurs
  2. “At risk” patients: those with a history of diabetes, alcoholism, hepatitis, obesity and hyperlipidemia
  3. Patients taking methotrexate or tetracyclines
  4. Women who are breastfeeding


  • Oral Tablets: Acitretin 10 or 25 mg
  • Oral Capsules: Acitretin 10 or 25 mg
  • Available under the trade names Soriatane® and Neotigason®
  • Must be taken once a day with food, preferably fatty foods


  • Recommended initial dosage is 25 mg/day
  • Maintenance dose of 25-50 mg/day may be given after 12-16 weeks, based on clinical efficacy and tolerability
  • Do not exceed a maximum of 75 mg/day
  • Occasionally patients can be controlled with lower doses such as 25 mg 2 to 3 times a week

Stabilizing Keratinization (Off Label)

  • 25 mg daily May be increased up to 75 mg daily after four weeks if needed and tolerated